CME: Staging therapy in hypertrophic cardiomyopathy patients with heart failure: New insights Medical Education on ReachMD

Overview
Heart failure (HF) represents a major issue in patients with hypertrophic cardiomyopathy (HCM) as it is one of the leading causes of mortality in these patients. In this educational program, 3 experts discuss how to recognize and diagnose HF in patients with HCM and explore which therapeutic options are currently available for these patients.
This course consists of 3 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits.
Program Highlights
This educational program consists of 3 presentations on HF and HCM.
Recognizing and diagnosing heart failure in patients with HCM - Aleš Linhart, MD, PhD - Prague, Czech Republic
- HF is a major complication in patients with HCM. Aleš Linhart discusses which features of HCM may predict subsequent HF risk.
Optimal pharmacological management of HCM by clinical manifestations - Pablo García-Pavía, MD, PhD - Madrid, Spain
- “Hypertrophic cardiomyopathy is very heterogenous disease, ” says Pablo García-Pavía. Hear him discuss optimal pharmacological management in different clinical manifestations of HCM.
Evidence-based novel therapies in HCM - Michelle Michels, MD, PhD - Rotterdam, The Netherlands
- Michelle Michels discusses the evidence supporting the use of novel cardiac myosin inhibitors in obstructive HCM. Are these study findings in line with the first real-world data in obstructive HCM?
Instructions
- Watch the 3 lectures and answer the pre- and post-test questions
- Fill in the evaluation questions
- Download CME Certificate
For questions regarding this activity, please contact us at info@pace-cme.org.
Learning Objectives
For questions regarding this activity, please contact us at info@pace-cme.org.
- Recall the hypertrophic cardiomyopathy (HCM) phenotype with highest heart failure risk
- Discuss which features of HCM may predict subsequent HF risk
- Discuss the evidence supporting recommendations of recently published guidelines on cardiomyopathy
- Analyze the latest clinical data regarding the use of myosin inhibitors in patients with HCM
Target Audience
This activity has been designed to meet the educational needs of cardiologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with hypertrophic cardiomyopathy.
Accreditation and Credit Designation Statements
This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 40 minutes of effective education time.
Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
Commercial Support
Funding for this educational program was provided by an unrestricted educational grant from Bristol Myers Squibb.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-CME.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 07/02/2024
Expiration Date: 07/02/2025